Guidelines on hypertension in 2005: a commentary

Edward D Frohlich

doi:10.1038/ncpcardio0223 | Full Text | PDF (45K)

Do patient preferences reduce the validity of randomized trials?

doi:10.1038/ncpcardio0187 | Full Text | PDF (54K)

Increased clinical benefit of atorvastatin at high doses in stable coronary heart disease

doi:10.1038/ncpcardio0200 | Full Text | PDF (54K)

Effects of chlortalidone, amlodipine and lisinopril on cardiovascular disease in hypertensive black patients

doi:10.1038/ncpcardio0201 | Full Text | PDF (60K)

Novel anticoagulant therapy: safety and pharmacokinetics

doi:10.1038/ncpcardio0202 | Full Text | PDF (54K)

Renalase regulates blood pressure and cardiac function

doi:10.1038/ncpcardio0203 | Full Text | PDF (61K)

Evidence of a pharmacodynamic interaction between naproxen and low-dose aspirin

doi:10.1038/ncpcardio0204 | Full Text | PDF (54K)

Understanding early mortality after heart transplantation

doi:10.1038/ncpcardio0205 | Full Text | PDF (61K)

VEGF gene therapy in angina patients

doi:10.1038/ncpcardio0206 | Full Text | PDF (55K)

Cannabinoid-1-receptor blockade to treat obesity and cardiovascular risk factors

doi:10.1038/ncpcardio0207 | Full Text | PDF (55K)

Antibiotic treatment and coronary heart disease

doi:10.1038/ncpcardio0208 | Full Text | PDF (54K)

Magnesium can prevent postoperative atrial fibrillation

doi:10.1038/ncpcardio0209 | Full Text | PDF (54K)

Heritability of hypertension and stroke

doi:10.1038/ncpcardio0210 | Full Text | PDF (61K)

Cardiovascular risk factors in adolescence

doi:10.1038/ncpcardio0211 | Full Text | PDF (54K)

Diet and exercise training in obese children

doi:10.1038/ncpcardio0212 | Full Text | PDF (54K)

Should ximelagatran replace warfarin for stroke prevention in patients with atrial fibrillation?

Geoffrey A Donnan and John V Ly

doi:10.1038/ncpcardio0216 | Full Text | PDF (67K)

Can creatine kinase MB levels predict mortality after cardiac surgery?

Allan S Jaffe

doi:10.1038/ncpcardio0218 | Full Text | PDF (68K)

Fractional flow reserve: can it predict adverse events accurately after coronary stenting?

Steven AJ Chamuleau

doi:10.1038/ncpcardio0219 | Full Text | PDF (68K)

Should patients with combined hyperlipidemia receive statin–fibrate combination therapy?

Antonio M Gotto Jr

doi:10.1038/ncpcardio0217 | Full Text | PDF (68K)

Can bedside testing of B-type natriuretic peptide be used to diagnose left-ventricular diastolic dysfunction?

Torbjørn Omland

doi:10.1038/ncpcardio0215 | Full Text | PDF (68K)

Cardiac resynchronization therapy: does varying the pacing site or combination of sites improve cardiac function?

Angelo Auricchio

doi:10.1038/ncpcardio0222 | Full Text | PDF (67K)

Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?

Gary Spektor and Valentin Fuster

doi:10.1038/ncpcardio0214 | Full Text | PDF (204K)

Mechanisms of Disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis

Robin P Choudhury, Justin M Lee and David R Greaves

doi:10.1038/ncpcardio0195 | Full Text | PDF (272K)